Consolidated Condensed Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Expenses
Research and development	$ 947,249	$ 2,141,945	$ 1,966,369	$ 4,076,588
General and administrative	874,884	1,011,879	1,861,354	1,756,500
Operating expenses	1,822,133	3,153,824	3,827,723	5,833,088
Other loss (income)
Change in fair value of derivative liability	(1,261)	889	(1,041)	(55,679)
Foreign exchange loss	5,097	7,120	10,935	50,986
Interest income	(16,272)	(235)	(36,116)	(391)
Other loss (income)	(12,436)	7,774	(26,222)	(5,084)
Net and comprehensive loss for the period	1,809,697	3,161,598	3,801,501	5,828,004
Computation of basic loss per share
Net and comprehensive loss for the period	1,809,697	3,161,598	3,801,501	5,828,004
Series B Preferred stock dividend	16,190	54,066	52,275	95,732
Net and comprehensive loss available to common stockholders	$ 1,825,887	$ 3,215,664	$ 3,853,776	$ 5,923,736
Basic and fully diluted loss per share	$ 0.08	$ 0.14	$ 0.16	$ 0.31
Basic weighted average number of shares	24,242,223	22,559,234	23,605,657	18,882,259